Refine
Year of publication
- 2011 (130) (remove)
Document Type
- Article (118)
- Doctoral Thesis (5)
- Part of a Book (4)
- Conference Proceeding (2)
- Preprint (1)
Language
- English (130) (remove)
Has Fulltext
- yes (130) (remove)
Is part of the Bibliography
- no (130)
Keywords
- mitochondria (3)
- Hepatocellular carcinoma (2)
- TRAIL (2)
- Transarterial chemoembolization (2)
- apoptosis (2)
- chemotherapy (2)
- ADAM-17 (1)
- Actaea cimicifuga (1)
- Allochromatium vinosum (1)
- Alzheimer's disease (1)
- Alzheimer’s disease (1)
- Antiangiogenesis (1)
- Antiviral therapy (1)
- Aortic Valve Replacement (1)
- Arrhythmia (1)
- Attention (1)
- Autism (1)
- BCR/ABL (1)
- Black cohosh (1)
- Black cohosh induced liver injury (1)
- Bottom-up (1)
- C-clamp (1)
- CYP450 (1)
- Capsule endoscopy (1)
- Cardiac arrest (1)
- Cell Adhesion (1)
- Clinical Skills (1)
- Competencies (1)
- Consensus methods (1)
- CoxVa (1)
- Crohn’s disease (1)
- Crossmodal (1)
- Cyclosporin A (1)
- Cytokines Induction (1)
- Delphi Survey (1)
- Directly acting antiviral agent (1)
- Drug induced liver injury (1)
- EET (1)
- ERP (1)
- EZ-IO® needle driver (1)
- Electroencephalography (1)
- Emergency medicine (1)
- Event-related potential (1)
- Functional connectivity (1)
- Functional magnetic resonance imaging (1)
- Gene Regulation (1)
- Generalized procrustes analysis (1)
- Genome-wide association study (1)
- Genomic medicine (1)
- H1N1 (1)
- HSCT (1)
- Hemagglutination inhibition assay (1)
- Hepatitis C virus (1)
- Hepatotoxicity (1)
- Herb induced liver injury (1)
- Herbal hepatotoxicity (1)
- Highwire (1)
- Human genetics (1)
- IAPs (1)
- ICD (1)
- Immunology (1)
- Immunosuppression (1)
- Independent component analysis (1)
- Individualized therapy (1)
- Inflammation (1)
- Inside-out Signaling (1)
- Integrin (1)
- Interferon-α (1)
- Interferon-λ, (1)
- Interleukin (1)
- Interleukin-22 (1)
- Intraosseous access (1)
- L2 (1)
- LFA-1 (1)
- Left Ventricular Mass (1)
- Local field potential (1)
- Lymphocyte (1)
- MCAK (1)
- MDM2 (1)
- MYCBP2 (1)
- Mgm1p (1)
- Multisensory (1)
- Multiset independent component analysis (1)
- Neuron (1)
- Object perception (1)
- Objectives (1)
- Outcomes (1)
- P600 (1)
- PAM (1)
- PHR1 (1)
- PI3K (1)
- Pain (1)
- Parkinson’s disease (1)
- Personal medicine (1)
- Phase-reset (1)
- Philadelphia Chromosome-positive leukemia (1)
- Podospora anserina (1)
- Portal (1)
- Practical skills (1)
- Prospective randomized Analysis (1)
- Protein Translocation (1)
- SKAP1 (1)
- STDP (1)
- Schizophrenia (1)
- Sensory processing (1)
- Shunt (1)
- Single nucleotide polymorphism (1)
- Skills (1)
- Small bowel endoscopy (1)
- Sorafenib (1)
- Sudden cardiac death (1)
- Surrogate endpoint (1)
- T Cell Biology (1)
- T Cells (1)
- T-wave alternans (1)
- TIM23 (1)
- TKI (1)
- TRP Channels (1)
- TRPA1 (1)
- Thrombosis (1)
- Trafficking (1)
- Ubiquitin Ligase (1)
- Ventricular tachyarrhythmic event (1)
- Vision (1)
- acupuncture (1)
- adverse reaction (1)
- aging (1)
- anaemia (1)
- anoxygenic phototrophic sulfur bacteria (1)
- antibodies (1)
- asthma (1)
- attention (1)
- auditory language processing (1)
- auto-structure (1)
- autovaccine (1)
- biomarker (1)
- blood transfusion (1)
- brainstem (1)
- cancer (1)
- chemoresistance (1)
- chinese medicine (1)
- chromosome instability (1)
- competitive peptide (1)
- dementia (1)
- dermatomes (1)
- dissimilatory sulfite reductase (1)
- drug resistance and invasiveness (1)
- dsr genes (1)
- e-Learning (1)
- evaluation (1)
- frontotemporal lobar degeneration (1)
- head zones (1)
- healthcare worker (1)
- healthcare workers (1)
- hemorrhage (1)
- history of medicine (1)
- house dust mite allergy (1)
- human (1)
- hyperalgesia (1)
- i-AAA protease (1)
- image distortion (1)
- immunization (1)
- influenza (1)
- integrate and fire (1)
- kyphosis (1)
- lactate (1)
- medical education (1)
- membrane protein (1)
- mitotic kinases (1)
- molecular targeted drugs (1)
- molecular targeting (1)
- multimedia (1)
- needle displacement (1)
- neurodegenerative diseases (1)
- nociceptors (1)
- non-Poissonian (1)
- novel H1N1 influenza (1)
- nutlin-3 (1)
- oddbal (1)
- oligomerization (1)
- orthodeoxia (1)
- orthopaedic surgery (1)
- overreaching markers (1)
- p38 MAPK (1)
- p53 (1)
- pain (1)
- pancreatic cancer (1)
- patent foramen ovale (1)
- pathology (1)
- pelvic injury (1)
- pelvic packing (1)
- pertussis (1)
- platypnea (1)
- preoperative assessment (1)
- preoperative preparation (1)
- prostate brachytherapy (1)
- proteasome inhibitor (1)
- protein quality control (1)
- racket sports (1)
- radiotherapy (1)
- referred pain (1)
- reflexes (1)
- regularity (1)
- regulation (1)
- sEH (1)
- safety (1)
- soluble tumor necrosis factor receptor (1)
- sox genes (1)
- speech segmentation (1)
- spike train (1)
- strength and conditioning mesocycle (1)
- sulfur globules (1)
- temperature (1)
- temporal correlations (1)
- thiosulfate oxidation (1)
- timing (1)
- tolerability (1)
- toxicity (1)
- transcatheter closure (1)
- trochee (1)
- tumor necrosis factor converting enzyme (1)
- ultrasound (1)
- vaccination rates (1)
- viscero-cutaneous (1)
Institute
- Medizin (130) (remove)
Introduction: As the immunosuppressive potency of 15-deoxyspergualin (DSG) has been shown in the therapy of renal transplant rejection and Wegener's granulomatosis, the intention of this study was to evaluate the safety of DSG in the therapy of lupus nephritis (LN). Methods: Patients with histologically proven active LN after prior treatment with at least one immunosuppressant were treated with 0.5 mg/kg normal body weight/day DSG, injected subcutaneously for 14 days, followed by a break of one week. These cycles were repeated to a maximum of 9 times. Doses of oral corticosteroids were gradually reduced to 7.5 mg/day or lower by cycle 4. Response was measured according to a predefined decision pattern. The dose of DSG was adjusted depending on the efficacy and side effects. Results: 21 patients were included in this phase-I/II study. After the first DSG injection, one patient was excluded from the study due to renal failure. 5 patients dropped out due to adverse events or serious adverse events including fever, leukopenia, oral candidiasis, herpes zoster or pneumonia. 11/20 patients achieved partial (4) or complete responses (7), 8 were judged as treatment failures and one patient was not assessable. 12 patients completed all 9 cycles; in those patients, proteinuria decreased from 5.88g/day to 3.37g/day (P = 0.028), Selena-SLEDAI decreased from 17.6 to 11.7. In 13/20 patients, proteinuria decreased by at least 50%; in 7 patients to less than 1g/day. Conclusions: Although the number of patients was small, we could demonstrate that DSG provides a tolerably safe treatment for LN. The improvement in proteinuria encourages larger controlled trials.
TIM23-mediated insertion of transmembrane alpha-helices into the mitochondrial inner membrane
(2011)
While overall hydrophobicity is generally recognized as the main characteristic of transmembrane (TM) alpha-helices, the only membrane system for which there are detailed quantitative data on how different amino acids contribute to the overall efficiency of membrane insertion is the endoplasmic reticulum (ER) of eukaryotic cells. Here, we provide comparable data for TIM23-mediated membrane protein insertion into the inner mitochondrial membrane of yeast cells. We find that hydrophobicity and the location of polar and aromatic residues are strong determinants of membrane insertion. These results parallel what has been found previously for the ER. However, we see striking differences between the effects elicited by charged residues flanking the TM segments when comparing the mitochondrial inner membrane and the ER, pointing to an unanticipated difference between the two insertion systems. Keywords: CoxVa , membrane protein , Mgm1p , mitochondria , TIM23
Background: FTY720, an immunomodulator derived from a fungal metabolite which reduces circulating lymphocyte counts by increasing the homing of lymphocytes to the lymph nodes has recently gained interest in stroke research. The aim of this study was to evaluate the protective efficacy of FTY720 in cerebral ischemia in two different application paradigms and to gather first data on the effect of FTY720 on the rate of spontaneous bacterial infections in experimental stroke. Methods: Middle cerebral artery occlusion (MCAO) in C57BL/6 mice (strain J, groups of 10 animals) was performed with two different durations of ischemia (90 min and 3 h) and FTY720 was applied 2 h after vessel occlusion to study the impact of reperfusion on the protective potency of FTY720. Lesion size was determined by TTC staining. Mice treated with FTY720 or vehicle were sacrificed 48 h after 90 min MCAO to determine the bacterial burden in lung and blood. Results: FTY720 1 mg/kg significantly reduced ischemic lesion size when administered 2 h after the onset of MCAO for 3 h (45.4 +/- 22.7 mm3 vs. 84.7 +/- 23.6 mm3 in control mice, p = 0.001) and also when administered after reperfusion, 2 h after the onset of MCAO for 90 min (31.1 +/- 28.49 mm3 vs. 69.6 +/- 27.2 mm3 in control mice, p = 0.013). Bacterial burden of lung homogenates 48 h after stroke did not increase in the group treated with the immunomodulator FTY720 while there was no spontaneous bacteremia 48 h after MCAO in treated and untreated animals. Conclusions: Our results corroborate the experimental evidence of the protective effect of FTY720 seen in different rodent stroke models. Interestingly, we found no increase in bacterial lung infections even though FTY720 strongly reduces the number of circulating leukocytes.
NK cells are part of the innate immune system, and are important players in the body’s first defence line against virus-infected and malignantly transformed cells. While T cells recognize neoplastic cells in an MHC-restricted fashion, NK cells do not require prior sensitization and education about the target. In leukemia and lymphoma patients undergoing allogeneic hematopoietic stem cell transplantation not only T cells but also NK cells have been found to mediate potent graft-versus-tumor effects. Hence, autologous or donor-derived NK cells hold great promise for cancer immunotherapy. Since the generation of highly purified NK cell products for clinical applications is labor-intensive and time consuming, established human NK cell lines such as NK-92 are also being considered for clinical protocols. NK-92 cells display phenotypic and functional characteristics similar to activated primary NK cells. While NK-92 cells are highly cytotoxic towards malignant cells of hematologic origin, they do not affect healthy human tissues. NK-92 cells can be expanded under GMP-compliant conditions, and can therefore be provided in sufficient numbers with defined phenotypic characteristics for clinical applications. Safety of NK-92 cells for adoptive immunotherapy was already shown in two phase I/II clinical trials...
Background: Although literature provides support for cognitive behavioral therapy (CBT) as an efficacious intervention for social phobia, more research is needed to improve treatments for children. Methods: Forty four Caucasian children (ages 8-14) meeting diagnostic criteria of social phobia according to the Diagnostic and Statistical Manual of Mental Disorders (4th ed.; APA, 1994) were randomly allocated to either a newly developed CBT program focusing on cognition according to the model of Clark and Wells (n = 21) or a wait-list control group (n = 23). The primary outcome measure was clinical improvement. Secondary outcomes included improvements in anxiety coping, dysfunctional cognitions, interaction frequency and comorbid symptoms. Outcome measures included child report and clinican completed measures as well as a diagnostic interview. Results: Significant differences between treatment participants (4 dropouts) and controls (2 dropouts) were observed at post test on the German version of the Social Phobia and Anxiety Inventory for Children. Furthermore, in the treatment group, significantly more children were free of diagnosis than in wait-list group at post-test. Additional child completed and clinician completed measures support the results. Discussion: The study is a first step towards investigating whether CBT focusing on cognition is efficacious in treating children with social phobia. Future research will need to compare this treatment to an active treatment group. There remain the questions of whether the effect of the treatment is specific to the disorder and whether the underlying theoretical model is adequate. Conclusion: Preliminary support is provided for the efficacy of the cognitive behavioral treatment focusing on cognition in socially phobic children. Active comparators should be established with other evidence-based CBT programs for anxiety disorders, which differ significantly in their dosage and type of cognitive interventions from those of the manual under evaluation (e.g. Coping Cat).
Background: Although being considered as a rarely observed HIV-1 protease mutation in clinical isolates, the L76V-prevalence increased 1998-2008 in some European countries most likely due to the approval of Lopinavir, Amprenavir and Darunavir which can select L76V. Beside an enhancement of resistance, L76V is also discussed to confer hypersusceptibility to the drugs Atazanavir and Saquinavir which might enable new treatment strategies by trying to take advantage of particular mutations. Results: Based on a cohort of 47 L76V-positive patients, we examined if there might exist a clinical advantage for L76V-positive patients concerning long-term success of PI-containing regimens in patients with limited therapy options. Genotypic- and phenotypic HIV-resistance tests from 47 mostly multi-resistant, L76V-positive patients throughout Germany were accomplished retrospectively 1999-2009. Five genotype-based drug-susceptibility predictions received from online interpretation-tools for Atazanavir, Saquinavir, Amprenavir and Lopinavir, were compared to phenotype-based predictions that were determined by using a recombinant virus assay along with a Virtual Phenotype™(Virco). The clinical outcome of the L76V-adapted follow-up therapy was determined by monitoring viral load for 96 weeks. Conclusions: In this analysis, the mostly used interpretation systems overestimated the L76V-mutation concerning Atazanavir- and SQV resistance. In fact, a clear benefit in drug susceptibility for these drugs was observed in phenotype analysis after establishment of L76V. More importantly, long-term therapy success was significantly higher in patients receiving Atazanavir and/or Saquinavir plus one L76V-selecting drug compared to patients without L76V-selecting agents (p = 0.002). In case of L76V-occurrence ATV and/or SQV may represent encouraging options for patients in deep salvage situations.
Vacuum-assisted closure (VAC) of complex infected wounds has recently gained popularity among various surgical specialties. The system is based on the application of negative pressure by controlled suction to the wound surface. The effectiveness of the VAC System on microcirculation and the promotion of granulation tissue proliferation are proved. In our case report we illustrate a scenario were a patient developed severe bleeding from the ascending aorta by penetration of wire fragments in the vessel. We conclude that all free particles in the sternum have to be removed completely before negative pressure is used.
Background: Many cancer patients seek homeopathy as a complementary therapy. It has rarely been studied systematically, whether homeopathic care is of benefit for cancer patients. Methods: We conducted a prospective observational study with cancer patients in two differently treated cohorts: one cohort with patients under complementary homeopathic treatment (HG; n=259), and one cohort with conventionally treated cancer patients (CG; n=380). For a direct comparison, matched pairs with patients of the same tumour entity and comparable prognosis were to be formed. Main outcome parameter: change of quality of life (FACT-G, FACIT-Sp) after 3 months. Secondary outcome parameters: change of quality of life (FACT-G, FACIT-Sp) after a year, as well as impairment by fatigue (MFI) and by anxiety and depression (HADS). Results: HG: FACT-G, or FACIT-Sp, respectively improved statistically significantly in the first three months, from 75.6 (SD 14.6) to 81.1 (SD 16.9), or from 32.1 (SD 8.2) to 34.9 (SD 8.32), respectively. After 12 months, a further increase to 84.1 (SD 15.5) or 35.2 (SD 8.6) was found. Fatigue (MFI) decreased; anxiety and depression (HADS) did not change. CG: FACT-G remained constant in the first three months: 75.3 (SD 17.3) at t0, and 76.6 (SD 16.6) at t1. After 12 months, there was a slight increase to 78.9 (SD 18.1). FACIT-Sp scores improved significantly from t0 (31.0 - SD 8.9) to t1 (32.1 - SD 8.9) and declined again after a year (31.6 - SD 9.4). For fatigue, anxiety, and depression, no relevant changes were found. 120 patients of HG and 206 patients of CG met our criteria for matched-pairs selection. Due to large differences between the two patient populations, however, only 11 matched pairs could be formed. This is not sufficient for a comparative study. Conclusion: In our prospective study, we observed an improvement of quality of life as well as a tendency of fatigue symptoms to decrease in cancer patients under complementary homeopathic treatment. It would take considerably larger samples to find matched pairs suitable for comparison in order to establish a definite causal relation between these effects and homeopathic treatment.
HDL, through sphingosine-1-phosphate (S1P), exerts direct cardioprotective effects on ischemic myocardium. It remains unclear whether other HDL-associated sphingophospholipids have similar effects. We therefore examined if HDL-associated sphingosylphosphorylcholine (SPC) reduces infarct size in a mouse model of transient myocardial ischemia/reperfusion. Intravenously administered SPC dose-dependently reduced infarct size after 30 minutes of myocardial ischemia and 24 hours reperfusion compared to controls. Infarct size was also reduced by postischemic, therapeutical administration of SPC. Immunohistochemistry revealed reduced polymorphonuclear neutrophil recruitment to the infarcted area after SPC treatment, and apoptosis was attenuated as measured by TUNEL. In vitro, SPC inhibited leukocyte adhesion to TNFα-activated endothelial cells and protected rat neonatal cardiomyocytes from apoptosis. S1P3 was identified as the lysophospholipid receptor mediating the cardioprotection by SPC, since its effect was completely absent in S1P3-deficient mice. We conclude that HDL-associated SPC directly protects against myocardial reperfusion injury in vivo via the S1P3 receptor.
Forgotten features of head zones and their relation to diagnostically relevant acupuncture points
(2011)
In the 1890s Sir Henry Head discovered certain areas of the skin that develop tenderness (allodynia) in the course of visceral disease. These areas were later termed ‘Head zones’. In addition, he also emphasized the existence of specific points within these zones, that he called ‘maximum points’, a finding that seems to be almost forgotten today. We hypothesized that two important groups of acupuncture points, the diagnostically relevant Mu and Shu points, spatially and functionally coincide with these maximum points to a large extent. A comparison of Head's papers with the Huang Di Neijing (Yellow Thearch's Inner Classic) and the Zhen Jiu Jia Yi Jing (Systematic Classic of Acupuncture and Moxibustion), two of the oldest still extant Chinese sources on acupuncture, revealed astonishing parallels between the two concepts regarding both point locations and functional aspects. These findings suggest that the Chinese discovery of viscerocutaneous reflexes preceded the discovery in the West by more than 2000 years. Furthermore, the fact that Chinese medicine uses Mu and Shu points not only diagnostically but also therapeutically may give us new insights into the underlying mechanisms of acupuncture.